ArticleBMC nephrology2025
The association between miR-632 and major adverse cardiovascular and cerebrovascular events in patients with end-stage renal disease undergoing long-term hemodialysis.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMajor adverse cardiovascular and cerebrovascular events (MACCE) are the primary cause of poor prognosis and mortality in patients with end-stage renal disease (ESRD), posing a serious threat to their health. Investigating the risk factors for MACCE in long-term hemodialysis patients with ESRD is of great significance for improving treatment outcomes and patient prognosis.
methodsPeripheral blood samples were collected from participants, and RT-qPCR was employed to measure the expression levels of miR-632 and PKD1. Participants were followed for three years. The clinical significance of miR-632 in predicting the occurrence of MACCE was analyzed using Kaplan-Meier survival curves, multivariate logistic regression, and ROC curves.
resultsIn patients with ESRD undergoing long-term hemodialysis, the expression level of miR-632 is significantly elevated. This high expression is strongly associated with an increased incidence of MACCE. miR-632 has high predictive value for the occurrence of MACCE in ESRD patients.
conclusionsmiR-632 is a risk factor for MACCE in ESRD patients undergoing long-term hemodialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.